Knowledge Graphs for Pharma A perspective from the PhUSE Project ‘Clinical Trials Data as RDF’

Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS. With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.

Artificial intelligence (AI) - “getting computers to do things that normally require a human mind” - is routinely being put to good use when making pharma clinical development decisions.

What does the future of your drug discovery program look like? Many industry leaders are finding themselves in uncharted waters: the science is more sophisticated than ever, producing paradigm-altering treatments. But, historically high R&D costs and low success rates has emphasized the need to identify drugs focused on translationally-relevant targets in the most cost and time efficient way.

The frontiers of data sciences and real-world data represent promising areas of innovation and possibility for life sciences and health-care organizations, especially within precision medicine. These areas are continuously evolving, and there are questions about how to navigate this complex and rapidly evolving set of resources, capabilities, and organizations. This webinar, in partnership with the Kraft Precision Medicine Accelerator at the Harvard Business School, aims to provide a landscape of the organizations working in real-world data and advanced analytics, including artificial intelligence and machine learning, and provide commentary on the recent changes to space. It will introduce attendees to the Kraft Precision Medicine Accelerator and teach them about real-world data analytics technologies and data assets that may help advance their research agendas, determine the subject of collaborations, or serve as an investment target.